News
Malaria pill trialed to prevent COVID-19
A trial to see whether two anti-malarial drugs could prevent COVID-19 has begun in Brighton and Oxford.
Chloroquine, hydroxychloroquine or a placebo will be given to more than 40,000 healthcare workers from Europe, Africa, Asia and South America.
All the participants are staff who are in contact with COVID-19 patients.
US President Donald Trump was criticised this week after he said he had been taking hydroxychloroquine, despite warnings it might be unsafe.
The first UK participants in the global trial were enrolled yesterday at the Brighton and Sussex University Hospitals and the John Radcliffe Hospital in Oxford.
They will be given either hydroxychloroquine or a placebo for three months. At sites in Asia, participants will be given chloroquine or a placebo.
These are the first of a planned 25 UK sites, with results expected by the end of the year.
The trial is open to anyone delivering direct care to coronavirus patients in the UK, as long as they have not been diagnosed with COVID-19.
It will test whether the drugs can prevent healthcare workers exposed to the virus from contracting it.
One of the study’s leaders, Prof Nicholas White at the University of Oxford said: “We really do not know if chloroquine or hydroxychloroquine are beneficial or harmful against COVID-19.”
But, he said, a randomised controlled trial such as this one, where neither the participant nor the researchers know who has been given the drug or a placebo, was the best way to find out.
“A widely available, safe and effective vaccine may be a long way off,” said Prof Martin Llewelyn from Brighton and Sussex Medical School, who is also leading the study.
“If drugs as well-tolerated as chloroquine and hydroxychloroquine could reduce the chances of catching COVID-19, this would be incredibly valuable.”
The drugs can reduce fever and inflammation and are used as both a prevention and a treatment for malaria.
Hydroxychloroquine regulates the body’s immune response and is also used in the treatment of rheumatoid arthritis and Lupus – an inflammatory disease caused by an overactive immune system.
Lupus charities in the UK and US have raised concerns that demand for the drug associated with coronavirus could threaten the supply for patients who already rely on it. -BBC
The Accra High Court of Ghana has granted bail in the sum of GH¢30 million to Frederick Kumi, popularly known as Abu Trica, in a major development in his ongoing extradition case.
Abu Trica as part of the bail condition is expected to provide two sureties.
His lawyer, Oliver Barker-Vormawor, disclosed the decision in a Facebook post on Tuesday.
Frederick Kumi, also known as Abu Trica, has been at the centre of a prolonged legal process to extradite him.
The latest ruling allows him temporary freedom while legal proceedings continue.
His legal team is expected to provide further updates on the next steps in court.
By: Jacob Aggrey
The Public Accounts Committee (PAC) today commenced its second Zonal Public Hearing in Kumasi Ashanti Region to examine the 2024 Auditor-General’s Report on public schools and District Assemblies yesterday, April 20, 2026.
In her opening remarks, the Chairperson of the Committee, Abena Osei Asare noted that the Committee will consider four (4) Auditor – General’s reports, namely, District Assembly Common Fund (DACF) & Other Statutory Funds, The Accounts of District Assemblies for the Financial Year (IGF), Pre-University Education Institutions and lastly Colleges of Education in the year ending 31st December 2024.
She assured the various District Assemblies and other institutions invited to respond to infractions cited in the Auditor-General’s report that the Committee would be transparent in asking questions as well as granting opportunities to all to explain issues to the Committee.
Abena Osei Asare, allowed the Ranking Member of the Committee, Samuel Atta Mills to chair the sitting with the explanation that her government was in power then, therefore she could not chair over Auditor-General reports of 2024.
